SCHEMBL13871010

SCHEMBL13871010

C=C1CCC(n2c(C)nc3cc4ccccc4cc3c2=O)C(=O)N1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 15/20 0.60
CRBN Q96SW2 15/20 0.60
IKZF3 Q9UKT9 2/20 0.48
TNF P01375 1/20 0.48
IL1B P01584 1/20 0.48
GAA P10253 2/20 0.41
ALOX15 P16050 1/20 0.41
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 2/20 0.38
NPC1 O15118 1/20 0.38
USP2 O75604 1/20 0.38
GLA P06280 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ELANE P08246 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26192246 0.89 CRBN (0.77) DDB1CRBNIKZF3TNFIL1B
SCHEMBL3655358 0.89 CRBN (0.77) DDB1CRBNIKZF3TNFIL1B
SCHEMBL26192816 0.89 CRBN (0.77) DDB1CRBNIKZF3TNFIL1B
SCHEMBL20437026 0.87 DDB1 (0.78) DDB1CRBNIKZF3TNFIL1B
SCHEMBL18840440 0.85 DDB1 (0.53) DDB1CRBNIKZF3TNFIL1B
SCHEMBL23979477 0.84 DDB1 (0.67) DDB1CRBNIKZF3TNFIL1B
SCHEMBL13871003 0.81 CRBN (0.53) DDB1CRBNIKZF3TNFIL1B
SCHEMBL12638503 0.81 DDB1 (0.53) DDB1CRBNIKZF3TNFIL1B
SCHEMBL16768175 0.79 DDB1 (0.63) DDB1CRBNIKZF3TNFIL1B
SCHEMBL12638348 0.79 DDB1 (0.63) DDB1CRBNIKZF3TNFIL1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492395-B2 7-substituted quinazolinone compounds and compositions comprising the same CELGENE CORPORATION (US) 2013-07-23 US disclosed
US-20090093504-A1 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same CELGENE CORPORATION 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093504-A1 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same CYP3A7, CYP2D6, CYP2B6 DDB1 3263/4885CRBN 3949/4885IKZF3 4761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.